NEW YORK (GenomeWeb News) – Saladax Biomedical has appointed Mark Myslinski to the posts of senior VP and chief commercial officer. Myslinski recently was president and CEO of RedPath Integrated Pathology, where he helped to move the company from research and development to commercialization of a molecular diagnostic assay in a CLIA lab. He also has served as VP of evidence-based medicine at Ortho Clinical Diagnostics and as GM of molecular and cellular diagnostics at Veridex.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.